You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment

Article info

Article menu
XML
Basic tumor immunology
Original research
STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment

Authors

  • Manoj Chelvanambi Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Ronald J Fecek Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Jennifer L Taylor Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Walter J Storkus Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USADermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USAPathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USABioengineering, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA PubMed articlesGoogle scholar articles

Citation

Chelvanambi M, Fecek RJ, Taylor JL, et al
STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment
Journal for ImmunoTherapy of Cancer 2021;9:e001906. doi: 10.1136/jitc-2020-001906
Online issue publication 
January 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.